human reproduction open

ESHRE PAGES

Endometriosis classification systems: an international survey to map current knowledge and uptake^{†,‡}

International Working Group of AAGL, ESGE, ESHRE and WES, Krina T. Zondervan^{1,2}, Stacey Missmer^{3,4,5}, Mauricio S. Abrao^{6,7}, Jon I. Einarsson⁸, Andrew W. Horne ¹⁰, ⁹, Neil P. Johnson¹⁰, Ted T.M. Lee¹¹, John Petrozza ¹⁰, ¹², Carla Tomassetti^{13,14}, Nathalie Vermeulen ¹⁵, Grigoris Grimbizis¹⁶, and Rudy Leon De Wilde ¹⁷,*

¹Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford Endometriosis CaRe Centre, Oxford, UK ²University of Oxford, Wellcome Centre for Human Genetics, Oxford, UK ³Department of Obstetrics, Gynecology and Reproductive Biology, Michigan State University College of Human Medicine, East Lansing, MI, USA ⁴Department of Epidemiology, Harvard University T.H. Chan School of Public Health, Boston, MA, USA ⁵World Endometriosis Research Foundation, WERF, London, UK ⁶Disciplina de Ginecologia, Departamento de Obstetricia e Ginecologia, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil ⁷Gynecologic Division, BP—A Beneficencia Portuguesa de Sao Paulo, Sao Paulo, SP, Brazil ⁸Division of Minimally Invasive Gynecologic Surgery, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, USA ⁹University of Edinburgh, MRC Centre for Reproductive Health, QMRI, Edinburgh, UK ¹⁰Robinson Research Institute, University of Adelaide, Adelaide, SA, Australia ¹¹Department of Obstetrics and Gynecology, Massachusetts General Hospital Fertility Center, Boston, MA, USA ¹³Department of Obstetrics and Gynaecology, Leuven University Fertility Center, University Hospitals Leuven, Leuven, Belgium¹⁴Faculty of Medicine, Department of Development and Regeneration, LEERM (Lab of Endometrium, Endometriosis and Reproductive Medicine), KU Leuven, Leuven, Belgium ¹⁵ESHRE, Central Office, Strombeek-Bever, Belgium ¹⁶Ist Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece ¹⁷Carl von Ossietzky Universitat Oldenburg, University Hospital for Gynecology, Oldenburg, Germany

*Correspondence address. University Hospital for Gynecology, Pius-Hospital Oldenburg, Carl von Ossietzky University of Oldenburg, Georgstreet 12, 26121 Oldenburg, Germany. Tel: +49-441-229-1500; E-mail: rudy-leon.dewilde@pius-hospital.de; guidelines@eshre.eu bhttps://orcid.org/0000-0001-5759-9745

Submitted on January 11, 2022; resubmitted on January 11, 2022; editorial decision on January 12, 2022

STUDY QUESTION: Which classification system for endometriosis do clinicians use most frequently, and why?

SUMMARY ANSWER: Even with a high uptake of the three existing endometriosis classification systems, most clinicians managing endometriosis would like a new simple surgical descriptive system for endometriosis.

WHAT IS KNOWN ALREADY: In the field of endometriosis, several classifications, staging and reporting systems have been developed and published, but there are no data on the uptake of these systems in clinical practice.

STUDY DESIGN, SIZE, DURATION: A survey was designed using the online SurveyMonkey tool consisting of 11 questions concerning three domains—participants background, existing classification systems and intentions with regards to a new classification system for endometriosis. Replies were collected between 15 May and 1 July 2020.

PARTICIPANTS/MATERIALS, SETTING, METHODS: A cross-sectional study was performed to gather data on the current use of endometriosis classification systems, problems encountered and interest in a new simple surgical descriptive system for endometriosis. The particular focus was on the three systems most commonly used: the Revised American Society for Reproductive Medicine (rASRM) classification, the endometriosis fertility index (EFI), and the ENZIAN classification. Data were analysed to detect statistically significant differences among user groups.

MAIN RESULTS AND THE ROLE OF CHANCE: The final dataset included the replies of 1178 clinicians, including surgeons, gynaecologists, reproductive endocrinologists, fertility specialists and sonographers, all managing women with endometriosis in their clinical practice. Overall, 75.5% of the professionals indicate that they currently use a classification system for endometriosis. The rASRM classification

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

[†]ESHRE pages content is not externally peer reviewed. The manuscript has been approved by the Executive Committee of ESHRE.

⁺This article is published simultaneously, with permission, in HROpen, FACTS, VIEWS and VISION in Obgyn and Journal of Minimally Invasive Gynecology.

[©] The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology.

system was the best known and used system, while the EFI system and ENZIAN system were known by a majority of the professionals but used by only a minority. The lack of clinical relevance was most often selected as a problem with using any system. The vast majority of respondents replied positively to the question on whether they would use a simple surgical descriptive system available for endometriosis, if available.

LIMITATIONS, REASONS FOR CAUTION: While the total number of respondents was acceptable, some regions/professions were not sufficiently represented to draw conclusions.

WIDER IMPLICATIONS OF THE FINDINGS: The findings of the survey suggest that clinicians worldwide are open to using a new classification system for endometriosis that can achieve standardized reporting and is clinically relevant and simple. The findings therefore support future initiatives for the development of a new descriptive system for endometriosis and provide information on user expectations and conditions for universal uptake of such a system.

STUDY FUNDING/COMPETING INTEREST(S): The meetings and activities of the working group were funded by the American Association of Gynecologic Laparoscopists, European Society for Gynecological Endoscopy, ESHRE and World Endometriosis Society. A.W.H. reports grant funding from the MRC, NIHR, CSO, Roche Diagnostics, Astra Zeneca, Ferring, Charles Wolfson Charitable Trust, Standard Life, and consultancy fees from Roche Diagnostics, AbbVie, Nordic Pharma and Ferring, outside the submitted work. In addition, A.W.H. has a patent Serum biomarker for endometriosis pending. He is Chair of TSC for STOP-OHSS and CERM trials and Chair of RCOG Academic Board 2018–2021. M.A. reports being member of the executive board and vice president of AAGL. N.P.J. reports personal fees from Abbott, Guerbet, Myovant Sciences, Vifor Pharma, Roche Diagnostics outside the submitted work; he is also President of the World Endometriosis Society and chair of the trust board. S.M. reports grants from AbbVie, DoD, NIH and Marriot Family Foundation, honoraria from University British Columbia and WERF, support for speaking at conferences (ESHRE, CanSAGE, Endometriosis UK, UEARS, IFFS, IASP, National Endometriosis Network UK) participation on Advisory Boards from AbbVie and Roche, outside the submitted work. She also discloses having a leadership or fiduciary role in SWHR, WERF, WES, ASRM and ESHRE. C.T. reports grants, consulting and speakers' fees non-financial support and other from Merck SA, non-financial support and other consulting fees from Gedeon Richter and Nordic Pharma, and support for meeting attendance non-financial support from Ferring Pharmaceuticals, outside the submitted work and without private revenue. K.T.Z. reports grants from Bayer Healthcare, MDNA Life Sciences, Volition Rx, and Evotec (Lab282-Partnership programme with Oxford University), non-financial support from AbbVie Ltd, all outside the submitted work; and is a Board member (Secretary) of the World Endometriosis Society and World Endometriosis Research Foundation. J.P. reports personal fees from Hologic, Inc., outside the submitted work; he is also a member of the executive boards of ASRM and SRS. The other authors had nothing to disclose.

Key words: endometriosis / infertility / classification / staging / reporting / survey / revised American Society for Reproductive Medicine / endometriosis fertility index / ENZIAN

WHAT DOES THIS MEAN FOR PATIENTS?

Classification systems for endometriosis have been developed, but there is no data as to whether clinicians actually use them in the management of their patients in clinical practice. We have organized a large survey to gather this information, and we found that indeed a large number of clinicians use the existing classification systems. The clinicians also mentioned a number of issues with the existing classification systems, including that the systems may not be very relevant for the diagnosis or treatment of the patient, or that they are not linked to the patients' symptoms. Finally, the clinicians answering the survey made suggestions on how to improve the classification systems. The information collected is very valuable towards future updates of existing classification systems, or development of a new, simple and clinically relevant universal system.

Introduction

In the field of endometriosis, several classifications, staging and descriptive systems have been developed, however, none seem to be comprehensive, or correlate sufficiently with clinically relevant outcomes for general uptake. In an attempt to provide direction for the future development of a new endometriosis classification system that is clinically relevant, three essential projects were defined: to review existing classification and staging systems for endometriosis; to develop a standard glossary to be utilized across the field of endometriosis; and to assess the current knowledge and uptake of classification systems among practitioners in the field. In the first project, 22 published classification and staging systems for endometriosis were summarized as well as the studies evaluating these with regards to feasibility, validity and reproducibility (International Working Group of AAGL, ESGE, ESHRE and WES et al., 2021d,e,f). The second project resulted in the publication of a terminology for endometriosis (International Working Group of AAGL, ESGE, ESHRE and WES et al., 2021a,b,c). For the third project, considering the uptake of the different classification systems, we conducted a survey to find out whether clinicians were routinely using any classification for endometriosis in clinical practice, which system is used most frequently, and what the motivations of clinicians are to use, or not use, any classification in endometriosis. The current paper reports the results of the survey. Of particular focus were the three systems most commonly used: the Revised American Society for Reproductive Medicine (rASRM) classification (American Society for Reproductive Medicine, 1997), the endometriosis fertility index (EFI) (Adamson and Pasta, 2010) and the ENZIAN classification (Tuttlies *et al.*, 2005). With regards to the ENZIAN classification, a revised version of the classification, #ENZIAN (Keckstein *et al.*, 2021), has meanwhile been published, but this was not available and hence not considered when the survey was conducted.

Materials and methods

A cross-sectional study was conducted using an online survey, which focused on classification of endometriosis. The questions were drafted by an international group of experts in endometriosis representing four societies: the American Association of Gynecologic Laparoscopists (AAGL), European Society for Gynaecological Endoscopy (ESGE), ESHRE and the World Endometriosis Society (WES). The survey was conducted online and afterwards distributed amongst all members of the participating societies and the members of the American Society for Reproductive Medicine (ASRM).

The survey included 11 questions organized in three sections. The first section focused on the participants' background and included questions related to their country, professional status (profession, experience) and expertise in managing endometriosis patients (Supplementary Data 1). The second part of the survey focused on existing classification systems, and the third part on the uptake of a potential new descriptive system for endometriosis.


The survey was open between 15 May and 1 July 2020. Recruitment strategies included mass mailings by each of the participating societies and promotion on social media. A total of 1251 replies were received.


The results of the survey were exported to SPSS 19 (IBM Corp., Armonk, NY, USA) for Windows for further analysis. Analysis and comparisons were focused on respondents who treat patients with endometriosis in clinical practice. Two sub-analyses were conducted, comparing surgeons versus other physicians, and replies between different regions. Statistically significant differences (P < 0.05) were assessed through Chi-square analysis.

Results

Of the 1251 respondents to the survey, the majority represented Europe (40.8%) and North-America (28.8%) (Fig. 1). Figure 2 shows the frequencies of the profession of the respondents. For the final analysis, responders were restricted to practicing clinicians, which included non-gynaecologist surgeons and gynaecologist-surgeon ('–surgeon'), and gynaecologists not performing surgery, reproductive endocrinologists, fertility specialists and sonographers ('non-surgeon'). From these groups, nine respondents were excluded as they reported they did not manage women with endometriosis in their clinical practice. The final dataset included 1178 respondents. One-third of these reported managing less than 10 endometriosis patients per month, and this proportion did not differ between the surgeon and non-surgeon groups. Within the surgeon group, 85% reported performing more than five endometriosis surgeries per month (Fig. 2).







Knowledge and use of existing classification systems

The rASRM classification system was the best known and most frequently used system, with only 4.7% of the respondents indicating they did not know or use the system. The EFI system and ENZIAN system were known by 76.1% and 53.8% of respondents, respectively, but used by only a minority (27.3% for EFI, 17.6% for ENZIAN) (Fig. 3).

Overall, 75.5% of the respondents indicated that they currently use a classification system for endometriosis. One-third of the respondents further reported that they use more than one system (26.6% uses two systems, 8.1% uses three or more systems). The rASRM system was most often used. A minority of respondents (3.7%, n = 37) indicated that they use another published classification system (not ENZIAN, rARSM or EFI) or their own system (Fig. 4).




Figure 3. Knowledge and use of ENZIAN, rASRM and EFI. rASRM, Revised American Society for Reproductive Medicine; EFI, Endometriosis Fertility Index.




Figure 4. Current use of a classification system, and which system is used.

On the question of which problems responders had encountered with the existing classification systems, 22.7% replied that they do not encounter any problems. The remaining respondents indicated a variety of problems. The lack of clinical relevance (n = 341) was most often selected (Fig. 5).

Motivation to use a new simple surgical descriptive system for endometriosis

The vast majority of respondents (95.1%) replied positively to the question on whether they would use a simple surgical descriptive system for endometriosis, if available (Fig. 6). They indicated that standardization of reporting and prediction of response to treatment

would be the main motivating factors to do so. Of the 4.9% of respondents not motivated to use a new system, some explained they were happy with the existing systems, while others considered that classification in endometriosis was not needed or impossible. The rest of respondents would use the system if it included patient symptoms, was clinically relevant and/or complete.

Surgeon versus non-surgeon

The responses were compared between those respondents that indicated surgeon (non-gynaecologist) or gynaecologist-surgeon as their profession, and other clinicians (gynaecologists not performing surgery, reproductive endocrinologists, fertility specialists, sonographers)





Figure 5. Problems with use of the existing classification systems and reasons for not using a classification system.



(Table I). There were no clear differences between surgeons and nonsurgeons with regards to the knowledge and use of any classification systems, although surgeons more often reported using the ENZIAN classification (25.5% versus 7.7%, P = 0.00001). With regards to the reasons for not using a classification system, surgeons more often indicated the lack of clinical relevance compared to non-surgeons (75.0% versus 51.7%, P = 0.00058). With regards to a new descriptive system, surgeons more frequently reported the following motivations, compared to non-surgeons: to predict complexity to assist in surgical planning (50.4% versus 25.0%, P < 0.00001), billing purposes (15.8% versus 5.2%, P = 0.000017), standardization of reporting (79.6% versus 68.5%, P = 0.00026) and research purposes (42.9% versus 34.3%, P = 0.014).

Differences between regions

In the comparison by continent, there was significant variation in the frequency of professions of the respondents and consequently in the number of surgeries they performed (Table II), but the level of expertise with endometriosis (i.e. the number of patients seen in clinical practice) was similar. Across continents, between 73.5% and 80.4% of respondents stated they currently use a classification system. There was lower knowledge and use in North-America, as compared to the rest of the world concerning ENZIAN (32.0% versus 62.1%, P < 0.00001) and EFI (60.5% versus 82.0%, P < 0.00001). With regards to the primary motivation to use a descriptive system, standardization was most often selected in all continents, apart from Asia and South-America, where prediction of response to treatment was the primary

motivation. These results, specifically for Oceania and Africa, should be considered with caution considering the low number of replies from these areas.

Discussion

This report summarizes the replies of 1178 clinicians, including surgeons, gynaecologists, reproductive endocrinologists, fertility specialists and sonographers, all managing women with endometriosis in their clinical practice. Questions focused on the current use of endometriosis classification systems, problems encountered and interest in a new simple surgical descriptive system for endometriosis.

Overall, three-quarters of the respondents indicate that they use a classification system for endometriosis, with limited variation according to profession or location. The rASRM classification system, the oldest system, was the best known and used. The ENZIAN classification system, published in 2005, and the EFI system, published in 2010, were known by half of the respondents, but used less often, by one in five and one in four clinicians, respectively. The ENZIAN classification system was more often used by surgeons.

Our results highlight some problems with the currently available classification systems. The most often reported problem, both by physicians using a classification system and those that do not, is the lack of clinical relevance. The complexity of the currently available classification systems is also considered a barrier for uptake, which is in line with previous reports (Adamson, 2011; Johnson et al., 2017). It

 Table I Comparison of the replies of surgeons versus non-surgeons to questions in a survey on use of endometriosis classification systems.

		SUR	GEON†	NON-SU	JRGEON††	Chi-squar
		Ν	%	N	%	
DEMOGRAPHICS					•••••	
Continent	Africa	25	2.8%	14	5.2%	P = 0.004
	Asia	118	13.1%	45	16.6%	
	Europe	377	42.0%	101	37.3%	
	North-America	244	27.2%	73	26.9%	
	Oceania	53	5.9%	4	1.5%	
	South-America	81	9.0%	34	12.5%	
Endometriosis in clinical practice	None	0	0	0	0	P = 0.091
(n = 1169)	<10 patients per month	248	27.6%	89	32.8%	
	10–50 patients per month	507	56.5%	151	55.7%	
	>50 patients per month	143	15.9%	31	11.4%	
Endometriosis surgeries per month	None	21	2.3%	118	43.5%	P < 0.00 I
n = 1169)	<5	307	34.2%	100	36.9%	
	5–10	314	35.0%	32	11.8%	
	10-20	177	19.7%	16	5.9%	
	>20	79	8.8%	5	1.8%	
(NOWLEDGE AND USE OF EXISTIN	G SYSTEMS					
Enzian (n = 1122)	Knowledge	322	37.2%	85	33.2%	P = 0.00
	Use	165	19.1%	32	12.5%	
	No knowledge/use	379	43.8%	139	54.3%	
Revised ASRM system (n = 1122)	Knowledge	285	32.9%	84	32.8%	P=0.69
	Use	543	62.7%	157	61.3%	
	No knowledge/use	38	4.4%	15	5.9%	
Endometriosis fertility index	Knowledge	416	48.0%	132	51.6%	P=0.31
(EFI) (n = 1122)	Use	234	27.0%	72	28.1%	
	No knowledge/use	216	24.9%	52	20.3%	
Current use of any classification	Yes	650	75.1%	197	77.0%	P=0.54
system (n = 1122)	No	216	24.9%	59	23.0%	
Use of classification system	Total	568		130		P < 0.00
	Enzian*	145	25.5%	10	7.7%	
	rASRM	492	86.6%	117	90.0%	
	EFI	158	27.8%	42	32.3%	
	Other	34	6.0%	3	2.3%	
Problems with current	Total	642		192		P=0.15
lassification systems	None	181	28.2%	56	29.2%	
	Too complicated*	151	23.5%	31	16.1%	
	Not clinically relevant	273	42.5%	68	35.4%	
	Takes too much time	124	19.3%	36	18.8%	
	Other	92	14.3%	30	15.6%	

(continued)

		SUR	GEON†	NON-SU	JRGEON††	Chi-squar
		N	%	N	%	
Reasons for not using a	Total	216		58		P < 0.001
classification system	Existing systems are too complicated	90	41.7%	20	34.5%	
	Existing systems are not clin- ically relevant*	162	75.0%	30	51.7%	
	Existing systems take too much time to complete	69	31.9%	15	25.9%	
	Other reason	31	14.4%	17	29.3%	
NEW DESCRIPTIVE SYSTEM						
nterested in use of a simple surgical	Yes	816	95.7%	231	93.1%	P = 0.11
lescriptive system (n = 0)	No	37	4.3%	17	6.9%	
Primary motivation to use a	Total	853		248		P < 0.001
lescriptive system?	Predictor of response to treatment	563	66.0%	175	70.6%	
	Better patient care	422	49.5%	123	49.6%	
	Research purposes*	366	42.9%	85	34.3%	
	Standardization of reporting*	679	79.6%	170	68.5%	
	Billing purposes*	135	15.8%	13	5.2%	
	Predict complexity to assist in surgical planning*	430	50.4%	62	25.0%	
	Other	32	3.8%	10	4.0%	

Table | Continued

†Non-gynaecologist and gynaecologist surgeons.

++Gynaecologists not performing surgery, reproductive endocrinologists, fertility specialists, sonographers.

*Significant (P < 0.05) in comparing surgeons versus non-surgeons.

rASRM, Revised American Society for Reproductive Medicine.

should be noted, in this respect, that the results of the present survey reflect the ENZIAN classification, and can not necessarily be extrapolated to the revised version of the classification, #ENZIAN (Keckstein et al., 2021).

In contrast to the high uptake of the rASRM, ENZIAN and EFI systems, the vast majority of clinicians managing endometriosis intended to use a new simple surgical descriptive system for endometriosis if developed. Standardization of reporting and prediction of response to treatment would be the main motivating factors to do so: the latter is consistent with the lack of clinical relevance of the current available systems. Standardized reporting of surgical findings is implemented in the WERF EPHect (Becker et al., 2014) and CORDES (Vanhie et al., 2016) questionnaires, which are currently tools for research purposes and not intended for clinical reporting. Any new clinically relevant classification system would need to be designed based on robust data analysis, by a multidisciplinary team, including experts in classification system development and validated across settings for its intended utility. Currently, the EFI is the only classification for which such testing was conducted in multiple studies in different countries. It is vital that both design and validation studies of any new tool would require robust assessment of metrics such as association with patient outcomes, including prediction of response to treatment, if the tool is intended for this clinical purpose. A standardized reporting system and anatomical classification of the endometriosis findings is a necessity for the further development of a grading system for clinical prediction.

Although confined to the inherent limits of the methodology, this report provides relevant information with regards to the uptake of currently available systems and suggests that clinicians worldwide are open to using a new classification system for endometriosis that can achieve standardized reporting, and is clinically relevant and simple. These considerations should be taken into account in the development of future endometriosis classifications.

Supplementary data

Supplementary data are available at Human Reproduction Open online.

Data availability

All data are incorporated into the article and its online supplementary material.

		Ā	Africa	٩	Asia	Eur	Europe	North-	North-America	ŏ	Oceania	South-	South-America
		z	%	z	%	z	%	z	%	z	%	z	%
DEMOGRAPHICS	EMOGRAPHICS	•	•	•	•								•
Profession	Surgeon (non-gynaecologist)	0	0.0%	2	1.2%	m	0.6%	2	0.6%	0	0.0%	-	0.9%
	Gynaecologist-surgeon	25	64.1%	116	71.2%	374	78.2%	242	76.3%	53	93.0%	80	69.6%
	Gynaecologist not performing surgery	0	0.0%	2	1.2%	29	6.1%	m	0.9%	2	3.5%	S	4.3%
	Reproductive endocrinologist	m	7.7%	12	7.4%	23	4.8%	55	17.4%	_	I.8%	S	4.3%
	Fertility specialist	Ξ	28.2%	31	19.0%	47	9.8%	4	4.4%	-	I.8%	20	17.4%
	Sonographer	0	0.0%	0	0.0%	2	0.4%	_	0.3%	0	0.0%	4	3.5%
Endometriosis in clinical	<10 patients per month	8	46.2%	52	31.9%	124	25.9%	66	31.2%	6	15.8%	35	30.4%
practice (n = 69)	10–50 patients per month	17	43.6%	88	54.0%	281	58.8%	175	55.2%	38	66.7%	59	51.3%
	>50 patients per month	4	10.3%	23	14.1%	73	15.3%	43	13.6%	0	17.5%	21	18.3%
Endometriosis surgeries per	None	8	20.5%	21	12.9%	65	13.6%	22	6.9%	Μ	5.3%	20	17.4%
month (n = 1 169)	<5	4	35.9%	66	40.5%	148	31.0%	128	40.4%	Ξ	19.3%	40	34.8%
	5-10	0	25.6%	50	30.7%	145	30.3%	94	29.7%	17	29.8%	30	26.1%
	10–20	9	15.4%	16	9.8%	77	16.1%	51	16.1%	23	40.4%	20	17.4%
	>20	_	2.6%	01	6.1%	43	9.0%	22	6.9%	m	5.3%	Ŋ	4.3%
KNOWLEDGE AND USE OF EXISTING SYSTEMS	EXISTING SYSTEMS												
Enzian (n = 22)	Knowledge	4	35.9%	55	35.3%	186	41.0%	76	24.6%	20	35.7%	56	51.9%
	Use	9	15.4%	16	10.3%	130	28.6%	23	7.4%	4	7.1%	8	16.7%
	No knowledge/use	61	48.7%	85	54.5%	138	30.4%	210	68.0%	32	57.1%	34	31.5%
Revised ASRM system	Knowledge	15	38.5%	64	41.0%	146	32.2%	001	32.4%	01	17.9%	34	31.5%
(n = 1122)	Use	20	51.3%	85	54.5%	282	62.1%	200	64.7%	44	78.6%	69	63.9%
	No knowledge/use	4	10.3%	7	4.5%	26	5.7%	6	2.9%	2	3.6%	Ω	4.6%
Endometriosis fertility index	Knowledge	20	51.3%	8	51.9%	239	52.6%	125	40.5%	23	41.1%	60	55.6%
(EFI) (n = 1 22)	Use	4	35.9%	37	23.7%	136	30.0%	62	20.1%	21	37.5%	36	33.3%
	No knowledge/use	Ω	12.8%	38	24.4%	79	17.4%	122	39.5%	12	21.4%	12	11.1%
Current use of any classifica-	Yes	29	74.4%	117	75.0%	343	75.6%	227	73.5%	45	80.4%	86	79.6%
tion system (n = 1122)	No	0	25.6%	39	25.0%	Ξ	24.4%	82	26.5%	=	19.6%	22	20.4%
Use of classification system	Total	21		88		267		210		4		71	
	Enzian	2	9.5%	12	13.6%	113	42.3%	12	5.7%	0	0.0%	91	22.5%
	rASRM	18	85.7%	75	85.2%	226	84.6%	195	92.9%	38	92.7%	57	80.3%
	EH	9	28.6%	32	36.4%	06	33.7%	35	16.7%	01	24.4%	27	38.0%
	Other	0	0.0%	_	%	61	7.1%	œ	3.8%	9	14.6%	ć	4.2%

		Afi	Africa	A	Asia	Eu	Europe	North	North-America	ŏ	Oceania	South-	South-America
	-	z	%	z	%	z	%	z	%	z	%	z	%
Problems with current classi- Total	Total	28		115		335		226		45		85	
fication systems	None	8	28.6%	30	26.1%	105	31.3%	99	29.2%	Ξ	24.4%	17	20.0%
	Too complicated	4	14.3%	30	26.1%	60	17.9%	56	24.8%	16	35.6%	91	18.8%
	Not clinically relevant	01	35.7%	49	42.6%	121	36.1%	105	46.5%	25	55.6%	31	36.5%
	Takes too much time	7	25.0%	23	20.0%	52	15.5%	47	20.8%	0	22.2%	21	24.7%
	Other reason	m	10.7%	6	7.8%	58	17.3%	31	13.7%	9	13.3%	15	17.6%
Reasons for not using a classi- Total	Total	0		39		011		82		Ξ		22	
fication system	Existing systems are too complicated	4	40.0%	15	38.5%	49	44.5%	31	37.8%	9	54.5%	Ŋ	22.7%
	Existing systems are not clinically relevant	4	40.0%	21	53.8%	74	67.3%	72	87.8%	7	63.6%	4	63.6%
	Existing systems take too much time to complete	9	60.0%	13	33.3%	35	31.8%	24	29.3%	-	9.1%	S	22.7%
	Other reason	2	20.0%	9	15.4%	20	18.2%	<u>-</u>	15.9%	_	9.1%	9	27.3%
NEW DESCRIPTIVE SYSTEM													
Interested in use of a simple	Yes	37	97.4%	151	98.1%	413	94.3%	290	94.2%	50	89.3%	901	99.1%
surgical descriptive system (n = 1101)	No	_	2.6%	m	I.9%	25	5.7%	8	5.8%	9	10.7%	-	0.9%
Primary motivation to use a	Total	38		154		438		308		56		107	
descriptive system?	Predictor of response to treatment	25	65.8%	116	75.3%	277	63.2%	208	67.5%	31	55.4%	8	75.7%
	Better patient care	17	44.7%	84	54.5%	208	47.5%	163	52.9%	30	53.6%	43	40.2%
	Research purposes	6	23.7%	52	33.8%	185	42.2%	145	47.1%	26	46.4%	34	31.8%
	Standardization of reporting	32	84.2%	102	66.2%	350	79.9%	242	78.6%	46	82.1%	77	72.0%
	Billing purposes	4	10.5%	9	3.9%	20	4.6%	102	33.1%	7	12.5%	6	8.4%
	Predict complexity to assist in surgical planning	<u>n</u>	34.2%	56	36.4%	186	42.5%	172	55.8%	20	35.7%	45	42.1%
		c	/00 0	L				-		•		I	100

Acknowledgements

The authors would like to acknowledge the professionals that have completed the survey and the societies that supported the dissemination of the survey, including the American Society of Reproductive Medicine (ASRM). The authors further would like to thank the experts that contributed to the stakeholder review for their useful comments.

Authors' roles

All authors contributed to conception and design of the survey, drafting the content and critically revising it. All authors approved the final version.

Funding

The meetings and activities of the working group were funded by the American Association of Gynecologic Laparoscopists, European Society for Gynaecological Endoscopy, ESHRE and World Endometriosis Society.

Conflict of interest

A.W.H. reports grant funding from the MRC, NIHR, CSO, Roche Diagnostics, Astra Zeneca, Ferring, Charles Wolfson Charitable Trust, Standard Life, and consultancy fees from Roche Diagnostics, AbbVie, Nordic Pharma and Ferring, outside the submitted work. In addition, A.W.H. has a patent Serum biomarker for endometriosis pending. He is Chair of TSC for STOP-OHSS and CERM trials and Chair of RCOG Academic Board 2018-2021. M.A. reports being member of the executive board and vice president of AAGL. N.P.J. reports personal fees from Abbott, Guerbet, Myovant Sciences, Vifor Pharma, Roche Diagnostics outside the submitted work; he is also President of the World Endometriosis Society and chair of the trust board. S.M. reports grants from AbbVie, DoD, NIH and Marriot Family Foundation, honoraria from University British Columbia and WERF, support for speaking at conferences (ESHRE, CanSAGE, Endometriosis UK, UEARS, IFFS, IASP, National Endometriosis Network UK) participation on Advisory Boards from AbbVie and Roche, outside the submitted work. She also discloses having a leadership or fiduciary role in SWHR, WERF, WES, ASRM and ESHRE. C.T. reports grants, consulting and speakers' fees from Merck SA, consulting fees from Gedeon Richter and Nordic Pharma, and support for meeting attendance from Ferring Pharmaceuticals, outside the submitted work and without private revenue. K.T.Z. reports grants from Bayer Healthcare, MDNA Life Sciences, Volition Rx and Evotec (Lab282-Partnership programme with Oxford University), non-financial support from AbbVie Ltd, all outside the submitted work; and is a Board member (Secretary) of the World Endometriosis Society and World Endometriosis Research Foundation. J.P. reports personal fees from Hologic, Inc., outside the submitted work; he is also a member of the executive boards of ASRM and SRS. The other authors had nothing to disclose.

References

- Adamson GD. Endometriosis classification: an update. *Curr Opin* Obstet Gynecol 2011;**23**:213–220.
- American Society for Reproductive Medicine. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. *Fertil Steril* 1997;**67**:817–821.
- Adamson GD, Pasta DJ. Endometriosis fertility index: the new, validated endometriosis staging system. *Fertil Steril* 2010;**94**: 1609–1615.
- Becker CM, Laufer MR, Stratton P, Hummelshoj L, Missmer SA, Zondervan KT, Adamson GD; WERF EPHect Working Group. World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonisation Project: I. Surgical phenotype data collection in endometriosis research. *Fertil Steril* 2014; 102:1213–1222.
- International Working Group of AAGL, ESGE, ESHRE and WES, Tomassetti C, Johnson NP, Petrozza J, Abrao MS, Einarsson JI, Horne AW, Lee TTM, Missmer S, Vermeulen N, Zondervan KT et *al.* An international terminology for endometriosis, 2021. *Facts Views Vis Obgyn* 2021a;**13**:295–304.
- International Working Group of AAGL, ESGE, ESHRE and WES, Tomassetti C, Johnson NP, Petrozza J, Abrao MS, Einarsson JI, Horne AW, Lee TTM, Missmer S, Vermeulen N et al. An international terminology for endometriosis, 2021. *Hum Reprod Open* 2021b;**2021**:hoab029.
- International Working Group of AAGL, ESGE, ESHRE and WES, Tomassetti C, Johnson NP, Petrozza J, Abrao MS, Einarsson JI, Horne AW, Lee TTM, Missmer S, Vermeulen N *et al*. An international terminology for endometriosis, 2021. *J Minim Invasive Gynecol* 2021c;**28**:1849–1859.
- International Working Group of AAGL, ESGE, ESHRE and WES, Vermeulen N, Abrao MS, Einarsson JI, Horne AW, Johnson NP, Lee TTM, Missmer S, Petrozza J, Tomassetti C et al. Endometriosis classification, staging and reporting systems: a review on the road to a universally accepted endometriosis classification. Hum Reprod Open 2021d;**2021**:hoab025.
- International Working Group of AAGL, ESGE, ESHRE and WES, Vermeulen N, Abrao MS, Einarsson JI, Horne AW, Johnson NP, Lee TTM, Missmer S, Petrozza J, Tomassetti C, Zondervan KT et al. Endometriosis classification, staging and reporting systems: a review on the road to a universally accepted endometriosis classification. *Facts Views Vis Obgyn* 2021e;**13**: 305–330.
- International Working Group of AAGL, ESGE, ESHRE and WES, Vermeulen N, Abrao MS, Einarsson JI, Horne AW, Johnson NP, Lee TTM, Missmer S, Petrozza J, Tomassetti C *et al.* Endometriosis classification, staging and reporting systems: a review on the road to a universally accepted endometriosis classification. *J Minim Invasive Gynecol* 2021f;**28**:1822–1848.
- Johnson NP, Hummelshoj L, Adamson GD, Keckstein J, Taylor HS, Abrao MS, Bush D, Kiesel L, Tamimi R, Sharpe-Timms KL et al.; World Endometriosis Society Sao Paulo Consortium. World Endometriosis Society consensus on the classification of endometriosis. Hum Reprod 2017;**32**:315–324.

- Keckstein J, Saridogan E, Ulrich UA, Sillem M, Oppelt P, Schweppe KW, Krentel H, Janschek E, Exacoustos C, Malzoni M *et al.* The #Enzian classification: a comprehensive non-invasive and surgical description system for endometriosis. *Acta Obstet Gynecol Scand* 2021;**100**:1165–1175.
- Tuttlies F, Keckstein J, Ulrich U, Possover M, Schweppe KW, Wustlich M, Buchweitz O, Greb R, Kandolf O, Mangold R et al.

[ENZIAN-score, a classification of deep infiltrating endometriosis]. Zentralbl Gynakol 2005;**127**:275–281.

Vanhie A, Meuleman C, Tomassetti C, Timmerman D, D'Hoore A, Wolthuis A, Van Cleynenbreugel B, Dancet E, Van den Broeck U, Tsaltas J et al. Consensus on recording deep endometriosis surgery: the CORDES statement. Hum Reprod 2016;31: 1219–1223.